Clinicopathologic factor | Total | Serum relaxin-2 | Relaxin-2 mRNA expression | |||
---|---|---|---|---|---|---|
(mean ± SEM) (ng/mL) | P-Value | Low(n) | High(n) | P-Value | ||
Sex | 0.456 | 0.568 | ||||
Female | 20 | 88.24 ± 13.27 | 7 | 13 | ||
Male | 16 | 91.58 ± 12.36 | 8 | 8 | ||
Age(Years) | 0.087 | 0.092 | ||||
<20 | 21 | 95.23 ± 14.16 | 6 | 15 | ||
≥20 | 15 | 83.62 ± 12.61 | 9 | 6 | ||
Tumor location | 0.562 | 0.67 | ||||
Extremity | 14 | 91.54 ± 15.13 | 6 | 8 | ||
Axial | 22 | 89.67 ± 14.86 | 9 | 13 | ||
Histologic subtypes | 0.893 | 0.746 | ||||
Osteoblastic | 12 | 91.65 ± 13.02 | 5 | 7 | ||
Chondroblastic | 10 | 90.54 ± 13.48 | 4 | 6 | ||
Fibroblastic | 9 | 89.04 ± 14.23 | 3 | 6 | ||
Telangiectactic | 5 | 91.86 ± 13.35 | 3 | 2 | ||
Clinical stage | 0.004 | 0.018 | ||||
I + II | 20 | 76. 4 ± 15.27 | 11 | 9 | ||
III | 16 | 114.53 ± 17.26 | 4 | 12 | ||
Hematogenous metastasis | 0.001 | 0.002 | ||||
No | 15 | 70.53 ± 10.42 | 11 | 4 | ||
Yes | 21 | 108.6 ± 14.87 | 4 | 17 | ||
Grade | 0.742 | |||||
High | 30 | 89.12 ± 13.90 | 0.642 | 11 | 19 | |
Moderate | 3 | 94.40 ± 12.16 | 2 | 1 | ||
Low | 3 | 96.18 ± 12.45 | 2 | 1 |